Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals
(KNSA)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Arcalyst
Rilonacept
2008-02-27
Inborn genetic diseases
,
Inflammation
,
Cryopyrin-associated periodic syndromes
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Rilonacept
recurrence
,
pericarditis
Mavrilimumab
respiratory insufficiency
,
sars-cov-2
,
severe acute respiratory syndrome-related coronavirus
,
arteritis
,
giant cell arteritis
,
polymyalgia rheumatica
,
covid-19
,
pneumonia
,
inflammation
Cilmostim
covid-19
,
pneumonia
,
inflammation
Ademetionine
recurrence
,
pericarditis
Regramostim
covid-19
,
pneumonia
,
inflammation
Molgramostim
covid-19
,
pneumonia
,
inflammation
Bevifimod
recurrence
,
pericarditis
VIXARELIMAB
pruritus
,
neurodermatitis
,
psoriasis
,
lichen planus
,
chronic urticaria
,
urticaria
,
prurigo
Corticoids
recurrence
,
pericarditis
,
arteritis
,
giant cell arteritis
,
polymyalgia rheumatica
Q2w
pruritus
,
neurodermatitis
,
prurigo
Sagramostim
covid-19
,
pneumonia
,
inflammation
Evidence
recurrence
,
pericarditis
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use